Goldman Sachs Group Inc Verve Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,048,066 shares of VERV stock, worth $4.77 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,048,066
Previous 1,288,249 18.64%
Holding current value
$4.77 Million
Previous $6.29 Million 19.31%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$4.4 - $7.86 $1.06 Million - $1.89 Million
-240,183 Reduced 18.64%
1,048,066 $5.07 Million
Q2 2024

Aug 13, 2024
BUY
$4.76 - $12.79 $2.18 Million - $5.85 Million
457,379 Added 55.05%
1,288,249 $6.29 Million
Q1 2024

May 15, 2024
BUY
$10.81 - $17.96 $3.86 Million - $6.42 Million
357,254 Added 75.43%
830,870 $11 Million
Q4 2023

Feb 13, 2024
BUY
$8.84 - $18.7 $2.37 Million - $5.01 Million
268,079 Added 130.43%
473,616 $6.6 Million
Q3 2023

May 14, 2024
SELL
$11.42 - $20.82 $3.06 Million - $5.58 Million
-268,079 Reduced 56.6%
205,537 $2.73 Million
Q3 2023

Nov 14, 2023
SELL
$11.42 - $20.82 $702,798 - $1.28 Million
-61,541 Reduced 23.04%
205,537 $2.73 Million
Q2 2023

May 14, 2024
BUY
$13.34 - $19.9 $55,160 - $82,286
4,135 Added 1.57%
267,078 $5.01 Million
Q2 2023

Aug 14, 2023
BUY
$13.34 - $19.9 $55,160 - $82,286
4,135 Added 1.57%
267,078 $5.01 Million
Q1 2023

May 14, 2024
SELL
$14.3 - $24.01 $1.88 Million - $3.15 Million
-131,291 Reduced 33.3%
262,943 $3.79 Million
Q1 2023

May 11, 2023
SELL
$14.3 - $24.01 $1.88 Million - $3.15 Million
-131,291 Reduced 33.3%
262,943 $3.79 Million
Q4 2022

May 14, 2024
BUY
$17.85 - $40.7 $1.62 Million - $3.7 Million
90,881 Added 29.96%
394,234 $7.63 Million
Q4 2022

Feb 13, 2023
BUY
$17.85 - $40.7 $1.62 Million - $3.7 Million
90,881 Added 29.96%
394,234 $7.63 Million
Q3 2022

May 14, 2024
BUY
$15.63 - $41.49 $3.57 Million - $9.48 Million
228,594 Added 305.77%
303,353 $10.4 Million
Q3 2022

Nov 10, 2022
BUY
$15.63 - $41.49 $3.57 Million - $9.48 Million
228,594 Added 305.77%
303,353 $10.4 Million
Q2 2022

May 14, 2024
SELL
$11.14 - $23.17 $4.44 Million - $9.24 Million
-398,857 Reduced 84.22%
74,759 $1.14 Million
Q2 2022

Aug 15, 2022
SELL
$11.14 - $23.17 $352,124 - $732,380
-31,609 Reduced 29.72%
74,759 $1.14 Million
Q1 2022

May 16, 2022
BUY
$20.92 - $39.36 $1.13 Million - $2.12 Million
53,968 Added 102.99%
106,368 $2.43 Million
Q4 2021

Feb 14, 2022
BUY
$31.94 - $54.82 $327,257 - $561,685
10,246 Added 24.31%
52,400 $1.93 Million
Q3 2021

Nov 10, 2021
BUY
$46.0 - $73.99 $1.94 Million - $3.12 Million
42,154 New
42,154 $1.98 Million

Others Institutions Holding VERV

# of Institutions
186
Shares Held
73.3M
Call Options Held
85K
Put Options Held
215K
View Full List

About Verve Therapeutics, Inc.

VERV Quotes by TradingView
  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $273M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email